glp-1 drug market Market: the rapid growth of the diabetes and obesity drugs GLP-1 Drugs Market Size to
Description
Loeser, R
In a statement, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, questioned whether the FDA's resolution of the shortage had taken into account demand for the compounded drug and "the number of patients wholl need to be transitioned from a compounded version to a FDA-approved version. "Thats likely hundreds of thousands of patients," Brunner said
All content is framed for research use only no clinical or therapeutic claims are made
Chris Serres: Thank you so much for doing it
